Professional Marketing briefs

Cegedim Dendrite will deploy a new customer help-desk tool to clients worldwide. Amdocs' Smart Agent Desktop, will automate current processes so that pharma clients receive global reports that help them pinpoint worldwide support issues.

Eisai received a DDMAC warning letter for a Dacogen patient-profile card, a sales aid used when detailing physicians. DDMAC said the card was misleading, because it minimizes risks, overstates efficacy and omits material facts.

Celgene is poised to bring Istodax to market after acquiring the firm that oversaw development, Gloucester Pharmaceuticals. An early 2010 launch is planned for the lymphoma drug.

A recommendation issued by the New Jersey Division of Consumer Affairs calls for a new Board of Medical Examiners rule requiring that 25% of licensed physicians' CME be obtained in evidence-based educational programs or academic detailing.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.